While most biotechs chase broad-spectrum solutions, Neurimmune is playing the long game: translating human immune memory into precision antibodies for the brain's most stubborn diseases. Their secret weapon isn't a machine—it's the human genome itself.

"They're not just making antibodies—they're mining human immune history to outsmart protein aggregation in the brain."

The company's traffic split is telling: 52% organic search vs. 34% direct. In biotech, where direct traffic often signals brand recall from conferences and partnerships, this suggests Neurimmune is building a moat of academic credibility. Their Zurich headquarters isn't just a location—it's a statement of access to Europe's densest cluster of neurology talent.

• Platform validated by human immune memory—de-risked from day one
• Zurich ecosystem access: proximity to ETH and pharma giants
• Dual revenue streams: partnerships + internal pipeline (CSF-1R program)
• Lean ops: $16M revenue with 80 employees = high capital efficiency